Eric S. Furman, Ph.D. focuses on patent protection and other forms of intellectual property protection for biotechnology, pharmaceuticals, and medical devices.
Eric’s practice includes strategic patent counseling and procurement, freedom to operate analysis, counseling on infringement and invalidity issues, licensing, and due diligence studies as related to negotiations for mergers and acquisitions.
He currently represents clients with technology in the fields of genetically modified plants using RNAi methodologies, genetically modified organisms, stem cells, CAR T cells, prostate cancer therapeutics and other oncology pharmaceuticals, vaccines, medical devices, dietary supplements, diagnostic devices and assays, cleantech, industrial chemicals, and cosmetics.
Before joining the firm, Eric was a research assistant in the laboratory of Dr. Leroy Hood where he made transgenic mice with aberrant forms of myelin basic protein. As a graduate student at the University of California, Los Angeles Medical School, he characterized transcription and splicing complexes, and was a teaching assistant for Donald S. Chisum, author of the preeminent treatise on patent law, while at law school.
University of Washington (UW), J.D.
University of California – Los Angeles – Medical School (UCLA), Ph.D., Biochemistry
University of New Mexico, B.S., Biology
State Bar of California
U.S. Patent and Trademark Office
Biotech
Aesthetic & Cosmetic Biotechnology
AgBio
Antibodies & Immunology
Biofuels
Biological Manufacturing of Chemicals
Biologics
CBD & Legal Cannabis
Diagnostic Tools
Genomics
Industrial Enzymes
Peptides
Personalized Medicine
Plant Patents
Research Tools & Reagents
Stem Cells & Regenerative Medicine
Synthetic Biology & Nanotechnology
Therapeutics
Tissue Engineering
Transgenic Animals
Transgenic Plants
Vaccines
Chemical, Industrial & Materials
Biochemistry
Building Construction
Building Products & Materials
Chemical Engineering
Construction & Home Improvement
Cosmetics & Personal Care Products
Food Chemistry
Furniture
Gardening
HVAC & Passive Ventilation
Mining Chemicals
Oil & Gas
Pharmaceutical Chemistry
Roofing
Consumer Products & Services
Aesthetics & Personal Care Products
Food & Beverage
Sporting Goods & Recreation
Electrical, Semiconductor & Computer Technology
Healthcare Information Technology
Energy
Biodegradable Materials
Bioenergy & Biofuels
Biomass
Clean Technology
Drinking Water Treatment
Emissions Abatement
Geothermal Energy
Green Building & Construction
Green Chemistry
Lighting
Remediation & Bioremediation
Wind Power
Financial Services & Business Methods
Licensing & Indemnification
Medical Devices & Procedures
Ablation Technology
Aesthetics & Implants
AI & Machine Learning
Annulus & Nucleus Repair
Dental Devices
Dermatology & Aesthetics
Diagnostics
Drug Eluting & Drug Delivery Devices
Imaging
Implants
Ischemic Stroke
Oncology
Pediatrics
Peripheral Artery Disease
Psychiatric & Neurological Conditions
Stents, Valves, & Delivery Systems
Tissue Engineering
Ventilators
Pharmaceuticals
Antibodies & Immunology
Biological Manufacturing of Chemicals
Biologics
Diagnostic Tools
Peptides
Personalized Medicine
Research Tools & Reagents
Stem Cells & Regenerative Medicine
Therapeutics
Vaccines
Transportation & Vehicles
Air conditioning / Heating systems
Fuels & Additives
Design Patents
Global Portfolio Management
Infringement Risk
Patent Strategy & Prosecution
Patentability
U.S. Patent Prosecution
Named amongst Top 30 for Most Active Attorneys in Biotech in Patexia’s Patent Intelligence 2023 Report
Named one of the “World’s Leading Patent Professionals” in the Patent 1000 guide by Intellectual Asset Management (IAM) magazine for Prosecution (2020-2023)
Named among the “Top 25 Intellectual Property Portfolio Managers & Patent Prosecutors” by the Daily Journal in 2015.
